A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes.

Trial Profile

A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Insulin degludec/liraglutide (Primary) ; Insulin degludec
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DUAL-II
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 15 Sep 2017 Results of a post hoc analysis assessing effect of IdegLira as a function of baseline renal function using patient data from DUAL I-V trials presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 15 Sep 2017 Results of pooled post-hoc analysis from two studies (DUAL II and DUAL V) presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 13 Sep 2017 According to a Novo Nordisk media release, results of post hoc analysis from DUAL II and DUAL V trials were presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top